Abstract
5603 Background: We evaluated the efficacy and toxicity of ifosfamide and doxorubicin chemotherapy regimen retrospectively in Turkish patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) previously treated with platinum-based chemotherapy Methods: A total of twenty-one patients with recurrent nasopharyngeal carcinoma who had received cisplatin based chemo-radiotherapy as a primary treatment were treated with ifosfamide 2500 mg/m2 days 1–3, mesna 2500 mg/m2 days 1–3, doxorubicin 60 mg/m2 day 1, repeated every 21 days. Eligible patients had measurable recurrent or metastatic disease, ECOG PS < 2, have adequate renal, hepatic and hematologic function. Results: Median age was 40 (range:17–54). Twenty of 21 patients were male; only one patient was female. Total 78 cycles of chemotherapy were introduced, and median cycles of chemotherapy for each patient is 3, (range:1–6). Sixteen patients were evaluable for toxicity and response. No patient achieved complete response and six partial response for a response rate of 37.5% in evaulable patients. Stable disease, and disease progression were observed in seven (43.8%) and three (18.7%) patients respectively. Clinical benefit was 68%. Median time to progression is 8.0 months Six patients had neutropenic fever as a result of chemotherapy and there were one treatment-related deaths due to tumor lysis syndrome at first cycle of the chemotherapy. There was no WHO grade 3 or 4 anemia, thrombocytopenia and cardiotoxicity. Treatments were generally well tolerated. Conclusions: Ifosfomide and doxorubicin combination is an effective regimen for the patients with recurrent and metastatic nasopharyngeal carcinoma. This combination may be considered as salvage therapy for NPC patients who failed to cisplatin based treatments No significant financial relationships to disclose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
